ORGENESIS INC. (OTCMKTS:ORGS) Files An 8-K Other Events
Item 8.01 Other Events.
On February 13, 2017, Orgenesis Inc. (the Company) announced that
the Companys Belgian-based subsidiary, Orgenesis SPRL, received
the formal approval from the Walloon Region, Belgium (Service
Public of Wallonia, DG06) for a 12.3 million (approximately $12.8
million) support program for the research and development of a
potential cure for Type 1 Diabetes. The financial support was
awarded to our Belgian subsidiary at 55% of budgeted costs, or a
total of 6.8 million (approximately $7 million).
A copy of our press release dated February 13, 2017 is furnished
herewith.
Item 9.01. Financial Statements and Exhibits.
| 99.1 | Press release dated February 13, 2017 |
About ORGENESIS INC. (OTCMKTS:ORGS)
Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development. ORGENESIS INC. (OTCMKTS:ORGS) Recent Trading Information
ORGENESIS INC. (OTCMKTS:ORGS) closed its last trading session up +0.020 at 0.700 with 4,200 shares trading hands.
